

Centre hospitalier universitaire vaudois



Poster : R-CPC-9

Antibiotic consumption to early detect epidemics of *P. aeruginosa* in a burn center: a paradigm shift in the epidemiological surveillance of *P. aeruginosa* nosocomial infections

Anne Fournier^{1,5}, Philippe Eggimann², Olivier Pantet², Marie Krähenbühl³, Claire-Lise Bonnemain³, Camille Fournier³, Jean-Luc Pagani², Jean-Pierre Revelly², Elise Dupuis-Lozeron⁴, Farshid Sadeghipour^{1,5}, André Pannatier¹, Pierre Voirol^{1,5}, Yok-Ai Que²

¹Pharmacy, ²Critical Care, ³Faculty of Biology and Medicine, CHUV, Lausanne; ⁴Research Center for Statistics, University of Geneva, Geneva, Geneva, Switzerland; ⁵ School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.

Introduction

The control of antibiotic resistance and nosocomial infections are major challenges for specialized burn

Conclusion

Our data support a **paradigm shift** in the **epidemiological surveillance** of **nosocomial** *P. aeruginosa* **epide-mics** in **burn centers**, using the rise in antibiotic consumption as an early trigger to initiate the molecular typing of *P. aeruginosa* strains and the reinforcement of standard infection control procedures.

centers¹. Early detection of those epidemic outbreaks is crucial to limit the human and financial burden.

Objectives

We hypothesize that data collected by antibiotic consumption medicoeconomic surveys² could be used as warning signal to detect early nosocomial outbreaks.



Lausanne Burn Intensive Care Unit (BICU)

inf

Methods

A retrospective analysis was conducted including all burn patients staying >48 h on the Lausanne BICU between **January 2001** and **October 2012** who received systemic therapeutic antibiotics. Infection episodes were characterized according to predefined criteria³⁻⁵. Based on the retrospective typing of the strains⁶, we defined a *P. aeruginosa* epidemic above the threshold of 25 infections/1000 burn-days (BD). Antibiotic consumption data, obtained from the quarterly surveillance of drug consumption surveys, were translated into defined daily doses (DDDs).



Figure 1: Number of infections according to isolated microorganisms over the study period.

Results

In total, **297** out of 414 burn patients stayed >**48h**, giving a total of 7458 BD. We identified **610 infection episodes** in **189 patients** (63.6%). **Burn wounds** (32.0%), **pulmonary** (31.1%) and **catheter infections** (21.8%) were the most prevalent types of infections. The most frequently isolated microorganisms were *P. aeruginosa* (26.2%), *S. aureus* (13.4%) and *C. albicans* (7.0%)



(**Fig. 1**). We observed 3 distinct outbreaks of *P. aeruginosa* infections (2002-2003, 2006 and 2009-2011). These outbreaks correlated with an increase in the DDDs of anti-*Pseudomonas* antibiotics (Spearman's rho=0.59, p=0.044) (**Fig. 2**).

Figure 2: Number of *P. aeruginosa* infections per 1000 burndays (right axis, in red) and DDDs of the most frequently used anti-*P. aeruginosa* antibiotics (left axis, cefepime, ciprofloxacin, ceftazidime, imipenem-cilastatin, meropenem, piperacillintazobactam in light grey bars; colistin in dark grey bars).

References

Enton de Vaude

- 1. Bloemsma et al. Mortality and causes of death in a burn centre. Burns : journal of the International Society for Burn Injuries. 2008; 34(8): 1103-7.
- 2. Carron et al. Five-year evolution of drug prescribing in a university adult intensive care unit. Applied health economics and health policy. 2012; 10(5): 355-8.
- 3. Levy et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive care medicine. 2003;29:530-8.
- 4. Greenhalgh et al. American Burn Association consensus conference to define sepsis and infection in burns. Journal of burn care & research. 2007;28:776-90.
- 5. Calandra et al. International Sepsis Forum Definition of Infection in the ICUCC. Critical care medicine. 2005;33:1538-48.
- 6. Cuttelod et al. Molecular epidemiology of Pseudomonas aeruginosa in intensive care units over a 10-year period (1998-2007); 2011;17:57-62.



Contact : <u>anne.henry@chuv.ch</u>

Disclosure of Interest: None Declared